Crizotinib Versus Conventional Chemotherapy in First-Line Treatment for ALK-Positive Non-Small Cell Lung Cancer: A Systematic Review and MetaAnalysis

Página do item simplificado
dc.creatorBarbara Delano Cruz
dc.creatorMariana M. Barbosa
dc.creatorLucas Torres
dc.creatorPâmela Azevedo
dc.creatorVânia E. A. Silva
dc.creatorBrian Godman
dc.creatorJuliana Alvares Teodoro
dc.date.accessioned2023-07-18T16:49:55Z
dc.date.accessioned2025-09-08T23:20:36Z
dc.date.available2023-07-18T16:49:55Z
dc.date.issued2021
dc.identifier.issn2366-1070
dc.identifier.urihttps://hdl.handle.net/1843/56590
dc.languagepor
dc.publisherUniversidade Federal de Minas Gerais
dc.relation.ispartofOncology and Therapy
dc.rightsAcesso Aberto
dc.subjectEficácia
dc.subjectMeta-analises
dc.subject.otherAnaplastic lymphoma kinase
dc.subject.otherCrizotinib
dc.subject.otherEffectiveness
dc.subject.otherEfficacy
dc.subject.otherLung cancer
dc.subject.otherSystematic review
dc.titleCrizotinib Versus Conventional Chemotherapy in First-Line Treatment for ALK-Positive Non-Small Cell Lung Cancer: A Systematic Review and MetaAnalysis
dc.typeArtigo de periódico
local.citation.epage524
local.citation.spage505
local.citation.volume9
local.description.resumoIntroduction Lung cancer is the most frequently diagnosed type of cancer and the main cause of death from malignant neoplasms worldwide. One of the most recent discoveries in the context of non-small cell lung cancer (NSCLC) was the mutation of the anaplastic lymphoma kinase receptor (ALK). This genetic alteration is found in approximately 2–5% of NSCLC patients, and crizotinib was the first targeted therapy discovered for its first-line treatment. Objective To conduct a systematic review and meta-analysis to estimate the magnitude of the overall survival (OS) and progression-free survival (PFS) from using crizotinib as treatment compared to traditional chemotherapy to guide future decision making. Methods PRISMA and Cochrane recommendations were followed using the findings based on studies published in the main international electronic databases. Selection criteria included the following: randomized clinical trials (RCT) or cohort studies that had assessed the efficacy and effectiveness of crizotinib as monotherapy in patients with NSCLC with ALK fusions. Results From 2504 publications identified in the literature, only eight publications referring to seven studies met the selection criteria, with high heterogeneity identified between the studies. Overall, there was a significant gain in PFS (HR 0.38; 95% CI 0.30–0.49; p < 0.00001); however, there was no significant gain in OS (HR 0.68; 95% CI 0.43–1.08; p = 0.10). Conclusion The study highlighted and confirmed that treatment with crizotinib led to clinical improvement in PFS among patients with advanced NSCLC with ALK fusion, as previously reported. However, there was no increase in overall survival in patients with NSCLC with genetic alterations of ALK. This must be considered when reviewing and funding treatments for NSCLC patients with this mutation.
local.identifier.orcidhttps://orcid.org/0000-0002-4106-7768
local.identifier.orcidhttps://orcid.org/0000-0002-7770-4597
local.identifier.orcidhttps://orcid.org/0000-0002-1947-6290
local.identifier.orcidhttps://orcid.org/0000-0001-6539-6972
local.identifier.orcidhttps://orcid.org/0000-0002-0210-0721
local.publisher.countryBrasil
local.publisher.departmentFAR - DEPARTAMENTO DE FARMÁCIA SOCIAL
local.publisher.initialsUFMG
local.url.externahttps://link.springer.com/article/10.1007/s40487-021-00155-3

Arquivos

Pacote original

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
Crizotinib Versus Conventional Chemotherapy in First-Line Treatment for ALK-Positive Non-Small Cell Lung Cancer A Systematic Review and Meta-Analysis.pdf
Tamanho:
7.65 MB
Formato:
Adobe Portable Document Format
Baixar

Licença do pacote

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
License.txt
Tamanho:
1.99 KB
Formato:
Plain Text
Descrição:
Baixar

Coleções

Artigo de Periódico

Logo UFMG